검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | encorafenib + binimetinib |
Overview Company | Strata Oncology |
Overview Modality | ADC |
Overview Target | Cancer |
Overview Indication | Cancer; Advanced Solid Tumor |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting a |
MoA Biomarker | PD-L1 expression |
PK/PD Half-life | 64 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Immune checkpoint inhibitor-associated lymphocytic colitis in a patient with metastatic melanoma.. We describe the case of a man in his 60s with metastatic melanoma on encorafenib/binimetinib and nivolumab/relatlimab, with a history of immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting and profuse watery diarrhoea. Investigations… |
Clinical Primary efficacy | ORR 66.7% |
Clinical ORR | 66.7% |
Clinical Result source | ClinicalTrials.gov NCT01543698 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | encorafenib + binimetinib |
Overview Company | Strata Oncology |
Overview Modality | ADC |
Overview Target | Cancer |
Overview Indication | Cancer; Advanced Solid Tumor |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting a |
MoA Biomarker | PD-L1 expression |
PK/PD Half-life | 64 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Immune checkpoint inhibitor-associated lymphocytic colitis in a patient with metastatic melanoma.. We describe the case of a man in his 60s with metastatic melanoma on encorafenib/binimetinib and nivolumab/relatlimab, with a history of immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting and profuse watery diarrhoea. Investigations… |
Clinical Primary efficacy | ORR 66.7% |
Clinical ORR | 66.7% |
Clinical Result source | ClinicalTrials.gov NCT01543698 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교